Analysts Expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) Will Post Earnings of -$0.86 Per Share

Analysts expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT – Get Rating) to report earnings of ($0.86) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Clarus Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($1.13). The firm is scheduled to report its next earnings […]

Related Keywords

,Schonfeld Strategic Advisors ,Powell Investment Advisors ,Clarus Therapeutics Company Profile Get Rating ,Zacks Investment Research ,Needham Company ,Blue Water Acquisition Corp ,Citadel Advisors ,Clarus Therapeutics Holdings Inc ,Clarus Therapeutics Inc ,Get Rating ,Clarus Therapeutic ,Clarus Therapeutics ,Investment Research ,Strategic Advisors ,Investment Advisors ,Therapeutics Company Profile ,Therapeutics Inc ,Nasdaq Crxt ,Crxt ,Medical ,Ratings ,Consensus ,